Saluda Medical Pty Ltd

Based in Australia, Saluda Medical Pty Ltd specializes in advanced neuromodulation technologies, focusing on the innovative treatment of chronic pain through its flagship Evoke® System, enhancing patient outcomes via precise spinal cord stimulation. Saluda Medical Pty Ltd, founded in 2011 in Macquarie Park, Australia, develops pioneering neuromodulation therapies for pain management. The company has raised USD 100. 00 mn in its most recent funding round, led by Redmile Group, with participation from various investors.

Jim Schuermann currently serves as CEO, steering the company through strategic advancements in chronic pain solutions. Saluda Medical focuses on advanced neuromodulation technologies, with its flagship product, the Evoke® System. This spinal cord stimulation system provides targeted pain relief by monitoring the spinal cord's physiological response using Evoked Compound Action Potentials (ECAPs). The Evoke® System is utilized primarily by patients with chronic trunk and limb pain, marketed predominantly in the United States and select international markets, with support from healthcare professionals and pain management specialists.

For the fiscal year 2024, Saluda Medical reported a revenue of USD 33. 89 mn, alongside an EBITDA of USD -62. 74 mn. The company's revenue model centers on the sale of the Evoke® System through partnerships with healthcare providers, hospitals, and pain management clinics, employing both direct-to-consumer and B2B strategies to enhance accessibility to its pain management solutions.

In January 2025, Saluda Medical raised USD 100 mn in venture funding to further its research and development efforts aimed at treating chronic neurological conditions, led by Redmile Group. The company plans to utilize this funding for upcoming product enhancements and to expand its market presence in new regions, focusing on innovative solutions for chronic pain management.